title: Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.
abstract: We evaluated demographic characteristics and graft composition as risk factors for acute graft-versus-host disease (GVHD) in 160 adult recipients of HLA-identical allogeneic blood stem cell transplants. The patients received a median nucleated cell dose of 7.9 x 10(8)/kg and median C34(+) cell dose of 5.6 x 10(6)/kg. GVHD prophylaxis consisted of cyclosporine (CSA) and steroids, tacrolimus (FK506) and steroids, or FK506 and methotrexate. Grades 2 to 4 GVHD occurred in 31% (95% CI, 23% to 39%), and grades 3 to 4 GVHD in 14% (95% CI, 8% to 20%). In univariate analyses, GVHD prophylaxis with CSA and high CD34(+) cell doses were significant risk factors for grades 2 to 4 GVHD, but diagnosis, age, use of total body irradiation, donor sex, female donor for male recipient, donor parity, donor alloimmunization, viral serology, nucleated cell dose, CD3(+) cell dose, and CD56(+) cell dose did not alter the incidence of GVHD significantly. With a CD34(+) cell dose less than 8 x 10(6) CD34(+) cells/kg, the risk of grades 2 to 4 GVHD was significantly higher for those who received CSA (39%, 95% CI, 21% to 47%) in comparison with those on FK506 (18%, 95% CI, 10% to 26%) (P =.03), but GVHD prophylaxis regimen had less impact with a higher CD34(+) cell dose (overall grades 2 to 4 GVHD rate 52%, 95% CI, 37% to 67%). GVHD prophylaxis and CD34(+) cell dose are independent risk factors for acute GVHD after allogeneic blood stem cell transplantation.
authors.affiliation: Departments of Blood and Marrow Transplantation, Biomathematics, Laboratory Medicine and Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. donnap@bcm.tmc.edu
authors.forename: D
authors.initials: D
authors.lastname: Przepiorka
authors.forename: T L
authors.initials: TL
authors.lastname: Smith
authors.forename: J
authors.initials: J
authors.lastname: Folloder
authors.forename: I
authors.initials: I
authors.lastname: Khouri
authors.forename: N T
authors.initials: NT
authors.lastname: Ueno
authors.forename: R
authors.initials: R
authors.lastname: Mehra
authors.forename: M
authors.initials: M
authors.lastname: Körbling
authors.forename: Y O
authors.initials: YO
authors.lastname: Huh
authors.forename: S
authors.initials: S
authors.lastname: Giralt
authors.forename: J
authors.initials: J
authors.lastname: Gajewski
authors.forename: M
authors.initials: M
authors.lastname: Donato
authors.forename: K
authors.initials: K
authors.lastname: Cleary
authors.forename: D
authors.initials: D
authors.lastname: Claxton
authors.forename: I
authors.initials: I
authors.lastname: Braunschweig
authors.forename: K
authors.initials: K
authors.lastname: van Besien
authors.forename: B S
authors.initials: BS
authors.lastname: Andersson
authors.forename: P
authors.initials: P
authors.lastname: Anderlini
authors.forename: R
authors.initials: R
authors.lastname: Champlin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology* / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens; D007166:Immunosuppressive Agents